Ignite Creation Date:
2024-05-06 @ 3:54 PM
Last Modification Date:
2024-10-26 @ 1:59 PM
Study NCT ID:
NCT04790409
Status:
COMPLETED
Last Update Posted:
2023-09-14
First Post:
2021-02-18
Brief Title:
Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations
Sponsor:
Zhejiang Cancer Hospital
Organization:
Zhejiang Cancer Hospital
Organization Data
Organization:
Zhejiang Cancer Hospital
Class:
OTHER
Study ID:
IRB-2019-81
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Zhejiang Cancer Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Fan Yun MD
Responsible Party Title:
MD
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Zhejiang Cancer Hospital
Old Name:
None
Old Organization:
None